Despoina Goniotaki

Despoina Goniotaki

Auto-generated profile, based on publicly available information

Despoina Goniotaki

Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience Maurice Wohl Clinical Neuroscience Institute King's College London London UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PBPhilipp Bethge
Philipp Bethge
SCStefano Carta
Stefano Carta
DLDayra A Lorenzo
Dayra A Lorenzo
LELadan Egolf
Ladan Egolf
DGDespoina Goniotaki
Despoina Goniotaki
FHFritjof Helmchen
Fritjof Helmchen
Genetically encoded calcium indicators (GECIs) enable imaging of in vivo brain cell activity with high sensitivity and specificity. In contrast to viral infection or in utero electroporation, indicator expression in transgenic reporter lines is induced noninvasively, reliably, and homogenously. Recently, Cre/tTA-dependent reporter mice were introduced, which provide high-level expression of green fluorescent GECIs in a cell-type-specific and inducible manner when crossed with Cre and tTA driver mice. Here, we generated and characterized the first red-shifted GECI reporter line of this type using R-CaMP1.07, a red fluorescent indicator that is efficiently two-photon excited above 1000 nm. By crossing the new R-CaMP1.07 reporter line to Cre lines driving layer-specific expression in neocortex we demonstrate its high fidelity for reporting action potential firing in vivo, long-term stability over months, and versatile use for functional imaging of excitatory neurons across all cortical layers, especially in the previously difficult to access layers 4 and 6.

27 November 2017 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
DGDespoina Goniotaki
Despoina Goniotaki
ALAsvin K K Lakkaraju
Asvin K K Lakkaraju
ASAmulya N Shrivastava
Amulya N Shrivastava
PBPamela Bakirci
Pamela Bakirci
SSSilvia Sorce
Silvia Sorce
AAAdriano Aguzzi
Adriano Aguzzi
Prion infections cause inexorable, progressive neurological dysfunction and neurodegeneration. Expression of the cellular prion protein PrPC is required for toxicity, suggesting the existence of deleterious PrPC-dependent signaling cascades. Because group-I metabotropic glutamate receptors (mGluR1 and mGluR5) can form complexes with the cellular prion protein (PrPC), we investigated the impact of mGluR1 and mGluR5 inhibition on prion toxicity ex vivo and in vivo. We found that pharmacological inhibition of mGluR1 and mGluR5 antagonized dose-dependently the neurotoxicity triggered by prion infection and by prion-mimetic anti-PrPC antibodies in organotypic brain slices. Prion-mimetic antibodies increased mGluR5 clustering around dendritic spines, mimicking the toxicity of Aβ oligomers. Oral treatment with the mGluR5 inhibitor, MPEP, delayed the onset of motor deficits and moderately prolonged survival of prion-infected mice. Although group-I mGluR inhibition was not curative, these results suggest that it may alleviate the neurological dysfunctions induced by prion diseases. Prion diseases are a result of ordered accumulation of the misfolded conformer of cellular prion protein (PrPC), a GPI anchored protein expressed on the cell surface. Similar pathogenetic principles operate in several other neurodegenerative diseases. Currently no disease-modifying therapies exist and the situation is compounded by a dearth of validated therapeutic targets. In our present study, we have discovered that genetic ablation, or pharmacological inhibition, of group-I (i.e. activating) metabotropic glutamate receptors is beneficial against prion neurotoxicity in vitro and in vivo. Mice treated with these inhibitors exhibited impressive suppression of neurological signs and a delayed onset of the symptoms. These results further suggest that activation of these metabotropic glutamate receptors is a downstream event of prion replication and targeting these receptors could be a therapeutic option to alleviate the neurological symptoms, thereby ameliorating the quality of life in patients having prion infection.

1 October 2013 in Molecular Therapy
Verified
Journal Article
Open access
SEStuart M Ellison
Stuart M Ellison
ATAntonio Trabalza
Antonio Trabalza
VTVeronica Tisato
Veronica Tisato
EPEvangelos Pazarentzos
Evangelos Pazarentzos
SLShirley H.F. Lee
Shirley H.F. Lee
NMNicholas D Mazarakis
Nicholas D Mazarakis
Huntington’s disease (HD) is a devastating neurodegenerative disorder caused by abnormal polyglutamine expansion in the huntingtin protein (Exp-Htt). Currently, there are no effective treatments for HD. We used bidirectional lentiviral transfer vectors to generate in vitro and in vivo models of HD and to test the therapeutic potential of vascular endothelial growth factor 165 (VEGF165). Lentiviral-mediated expression of Exp-Htt caused cell death and aggregate formation in human neuroblastoma SH-SY5Y and rat primary striatal cultures. Lentiviral-mediated VEGF165 expression was found to be neuroprotective in both of these models. Unilateral stereotaxic vector delivery of Exp-Htt vector in adult rat striatum led to progressive inclusion formation and striatal neuron loss at 10 weeks post-transduction. Coinjection of a lower dose VEGF165 significantly attenuated DARPP-32+ neuronal loss, enhanced NeuN staining and reduced Exp-Htt aggregation. A tenfold higher dose VEGF165 led to overt neuronal toxicity marked by tissue damage, neovascularization, extensive astrogliosis, vascular leakage, chronic inflammation and distal neuronal loss. No overt behavioral phenotype was observed in these animals. Expression of VEGF165 at this higher dose in the brain of wild-type rats led to early mortality with global neuronal loss. This report raises important safety concerns about unregulated VEGF165 CNS applications.

1 January 2019
Verified
Book Chapter
Closed access
PDF file
DHDiane P. Hanger
Diane P. Hanger
DGDespoina Goniotaki
Despoina Goniotaki
WNWendy Noble
Wendy Noble

4 October 2023 in Physical Review Research
Verified
Journal Article
Open access
PDF file
DBDavid Beers
David Beers
DGDespoina Goniotaki
Despoina Goniotaki
DHDiane P. Hanger
Diane P. Hanger
AGAlain Goriely
Alain Goriely
HHHeather A. Harrington
Heather A. Harrington
This paper is part of the Physical Review Research collection titled Physics of Neuroscience.

12 July 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
DGDespoina Goniotaki
Despoina Goniotaki
FTFrancesco Tamagnini
Francesco Tamagnini
LBLuca Biasetti
Luca Biasetti
SRSvenja‐Lotta Rumpf
Svenja‐Lotta Rumpf
CTClaire Troakes
Claire Troakes
DHDiane P. Hanger
Diane P. Hanger
INTRODUCTION: In tauopathies, altered tau processing correlates with impairments in synaptic density and function. Changes in hyperpolarization‐activated cyclic nucleotide‐gated (HCN) channels contribute to disease‐associated abnormalities in multiple neurodegenerative diseases.METHODS: To investigate the link between tau and HCN channels, we performed histological, biochemical, ultrastructural, and functional analyses of hippocampal tissues from Alzheimer's disease (AD), age‐matched controls, Tau35 mice, and/or Tau35 primary hippocampal neurons.RESULTS: Expression of specific HCN channels is elevated in post mortem AD hippocampus. Tau35 mice develop progressive abnormalities including increased phosphorylated tau, enhanced HCN channel expression, decreased dendritic branching, reduced synapse density, and vesicle clustering defects. Tau35 primary neurons show increased HCN channel expression enhanced hyperpolarization‐induced membrane voltage “sag” and changes in the frequency and kinetics of spontaneous excitatory postsynaptic currents.DISCUSSION: Our findings are consistent with a model in which pathological changes in tauopathies impact HCN channels to drive network‐wide structural and functional synaptic deficits.Highlights: Hyperpolarization‐activated cyclic nucleotide‐gated (HCN) channels are functionally linked to the development of tauopathy. Expression of specific HCN channels is elevated in the hippocampus in Alzheimer's disease and the Tau35 mouse model of tauopathy. Increased expression of HCN channels in Tau35 mice is accompanied by hyperpolarization‐induced membrane voltage “sag” demonstrating a detrimental effect of tau abnormalities on HCN channel function. Tau35 expression alters synaptic organization, causing a loosened vesicle clustering phenotype in Tau35 mice.